Peer-influenced content. Sources you trust. No registration required. This is HCN.

Physician’s WeeklyStandard Therapy Outperforms LAA Closure in High-Risk AF

CLOSURE-AF trial shows catheter-based LAA closure failed to match standard anticoagulation therapy in 912 high-risk AF patients (mean age 78). The device missed noninferiority for composite outcomes including stroke, bleeding, and cardiovascular death after 3-year follow-up across 42 German centers.


🔬 CLINICAL CONSIDERATIONS

  • LAA closure missed noninferiority threshold despite sealing the primary AF thrombus site. Standard anticoagulation provided superior composite endpoint protection in this elderly, high-risk population.
  • Bleeding concerns driving LAA referrals may be overweighted in clinical decision-making. Oral anticoagulation demonstrated strong net clinical benefit even in patients with elevated bleeding risk scores and documented bleeding histories.
  • Trial enrolled exceptionally high-risk population with mean age 78 and elevated CHAâ‚‚DSâ‚‚-VASc and HAS-BLED scores. Results should not be generalized to younger patients or moderate-risk AF cohorts where device outcomes may differ.
  • Procedural alternative failed where pharmacologic therapy succeeded in largest LAA closure trial to date. This challenges the assumption that device-based stroke prevention equals or surpasses guideline-directed medical therapy.
  • Study represents paradigm shift for high-risk elderly AF management. Prior expectations that LAA closure would prove comparable to anticoagulation were not supported by trial evidence in this vulnerable population.

🎯 PRACTICE APPLICATIONS

  • Maintain anticoagulation as first-line therapy for high-risk elderly AF despite bleeding history concerns
  • Document CLOSURE-AF findings when patients request LAA closure based on bleeding fear narratives from media
  • Reserve LAA closure for absolute anticoagulation contraindications, not relative bleeding risk elevation or patient preference
  • Counsel patients that procedural alternatives have not proven superior to optimized medical management in rigorous trials

More on Atrial Fibrillation (AF)

The Healthcare Communications Network is owned and operated by IQVIA Inc.

Click below to leave this site and continue to IQVIA’s Privacy Choices form